Iron Deficiency Anemia Treatments
Recommendations for the management of iron deficiency anemia including oral and intravenous iron therapies.
Diagnosis & Disease Information
Anticoagulant Dosing Conversions
Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
Manufacturing Deficiencies Delay Decision on Eflapegrastim
Eflapegrastim is a novel, long-acting G-CSF comprised of 2 protein components, an analogue of G-CSF and an Fc antibody fragment.
Highlights of the 2021 Joint Guidelines for Managing von Willebrand Disease
These guidelines from ASH, ISTH, NHF, and WFH are intended to support patients, clinicians, and healthcare professionals in their decisions affecting the management of VWD.
FDA Issues Guidance on Coagulation Systems to Measure Viscoelasticity During COVID-19 Pandemic
The FDA has issued guidance to facilitate the availability of coagulation systems during the COVID-19 pandemic.
Assessing Variations in Hematopoietic Stem Cell Transplant Referral Patterns for Children With Sickle Cell Disease
Investigators noted the importance of improving educational efforts about the safety and efficacy of matched sibling donor HSCT for children with sickle cell disease.
Narsoplimab Under Review for Stem Cell Transplant-Associated Thrombotic Microangiopathy
The FDA has accepted for filing and granted Priority Review to narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Hemoglobin Thresholds for Transfusion in Preterm Infants With Anemia
Study results suggest that a higher hemoglobin threshold may lead to more transfusions for preterm infants with anemia but without improving outcomes.
Durable Erythroid Response With Lenalidomide, Epoetin Alfa in Refractory Myelodysplastic Syndromes
A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.
First Treatment for Newly Diagnosed Light Chain Amyloidosis Approved
The approval was based on data from the open-label, active-controlled phase 3 ANDROMEDA study.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...